Skip to Main Content

Paper Details

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
NPJ Breast Cancer
57
2017
70-gene ultra-high risk signature, BRCA1/2, BRCA1ness, CIN70, DNA repair, DNA repair deficiency, HER2, HR, MP1, MP1/2, PARP1, PARP1 protein, PARPi-7, PARPi7, VC, Veliparib, breast cancer, carboplatin, patient, patients, triple, triple negative patients, veliparib
Author NameAffiliation
Denise M WolfUniversity of California san francisco
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Tesa M SeversonNetherlands Cancer Institute
William F SymmansUniversity of Texas
Melissa Paoloni
Melissa Paoloni
Donald A Berry
Laura J Van't VeerUniversity of California san francisco
  • 1 - 11

Datasets

Release 1.2